How many drugs treat Metastatic Breast Carcinoma?

Drug Landscape tracks 10 marketed treatments for Metastatic Breast Carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Metastatic Breast Carcinoma?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-breast-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic Breast Carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic Breast Carcinoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic Breast Carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Halaven	ERIBULIN	Eisai	Microtubule Inhibitor	Tubulin beta	2010-01-01
Ixempra Kit	IXABEPILONE	R-Pharm Us Llc	Microtubule Inhibitor	Apoptosis regulator Bcl-2	2007-01-01
Xeloda	capecitabine	Cheplapharm	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fareston	TOREMIFENE	Kyowa Kirin	Estrogen Agonist/Antagonist	5-hydroxytryptamine receptor 6	1997-01-01
Gemzar	gemcitabine	Accord Hlthcare	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	1996-01-01
Gemzar	Gemcitabine Hydrochloride	Accord Hlthcare	Nucleoside metabolic inhibitor	Ribonucleotide reductase; DNA incorporation	1996-01-01
Taxotere	Docetaxel	Sanofi	Microtubule Inhibitor [EPC]	Growth hormone-releasing hormone receptor	1996-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Metastatic Breast Carcinoma
Accord Hlthcare · 2 drugs in Metastatic Breast Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2 drugs in Metastatic Breast Carcinoma
Chipscreen Biosciences, Ltd. · 1 drug in Metastatic Breast Carcinoma
Eisai · 1 drug in Metastatic Breast Carcinoma
Extrovis · 1 drug in Metastatic Breast Carcinoma
Fudan University · 1 drug in Metastatic Breast Carcinoma
Johann Wolfgang Goethe University Hospital · 1 drug in Metastatic Breast Carcinoma
Kyowa Kirin · 1 drug in Metastatic Breast Carcinoma
M.D. Anderson Cancer Center · 1 drug in Metastatic Breast Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in Metastatic Breast Carcinoma
Pfizer Inc. · 1 drug in Metastatic Breast Carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic Breast Carcinoma:

Cite this brief

Drug Landscape (2026). Metastatic Breast Carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-breast-carcinoma. Accessed 2026-06-10.

Metastatic Breast Carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing